COX-2 Inhibitors as Adjunctive Therapy in SchizophreniaRationale for Use and Evidence to Date
作者:
Michael Riedel,
Martin Strassnig,
Markus J Schwarz,
Norbert Müller,
期刊:
CNS Drugs
(ADIS Available online 2005)
卷期:
Volume 19,
issue 10
页码: 805-819
ISSN:1172-7047
年代: 2005
出版商: ADIS
关键词: Celecoxib, therapeutic use;Cyclo oxygenase 2 inhibitors, therapeutic use;Schizophrenia
数据来源: ADIS
摘要:
A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.
点击下载:
PDF
(247KB)
返 回